HepaVac-101 First-in-man Therapeutic Cancer Vaccine Phase I/II Clinical Trial for Hepatocellular Carcinoma Patients.
Journal of clinical oncology（2018）
摘要
TPS3135Background: HCC is the third leading cause of death from cancer globally with an extremely variable 5-year survival rate. The HepaVac-101 phase I/II, first-in-man, therapeutic cancer vaccine...
更多查看译文
关键词
Hepatocellular Carcinoma,Cancer Immunotherapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要